{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:42:26Z","timestamp":1792078946979,"version":"4.4.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2015,10,15]],"date-time":"2015-10-15T00:00:00Z","timestamp":1444867200000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1111\/bjd.13932","type":"journal-article","created":{"date-parts":[[2015,6,3]],"date-time":"2015-06-03T11:14:57Z","timestamp":1433330097000},"page":"930-939","source":"Crossref","is-referenced-by-count":254,"title":["Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial"],"prefix":"10.1093","volume":"173","author":[{"given":"K.","family":"Papp","sequence":"first","affiliation":[{"name":"Probity Medical Research; 135 Union Street East Waterloo ON N2J 1C4 Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Comprehensive Center for Inflammation Medicine; University Medical School Schleswig-Holstein; University of L\u00fcbeck; L\u00fcbeck Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Reich","sequence":"additional","affiliation":[{"name":"SCIderm Research Institute and Dermatologikum Hamburg; Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Riedl","sequence":"additional","affiliation":[{"name":"Division of General Dermatology; Department of Dermatology; Medical University of Vienna; Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.","family":"Langley","sequence":"additional","affiliation":[{"name":"Dalhousie University; Halifax NS Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Krueger","sequence":"additional","affiliation":[{"name":"Laboratory for Investigative Dermatology; The Rockefeller University; New York NY U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.B.","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Tufts Medical Center; Boston MA U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.P.","family":"Bowman","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Li","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhou","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Shames","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc.; Kenilworth NJ U.S.A"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,10,15]]},"reference":[{"key":"10.1111\/bjd.13932-BIB0001|bjd13932-cit-0001","first-page":"280","article-title":"The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey","volume":"137","author":"Krueger","year":"2001","journal-title":"Arch Dermatol"},{"key":"10.1111\/bjd.13932-BIB0002|bjd13932-cit-0002","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000233234","article-title":"Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis","volume":"219","author":"Bansback","year":"2009","journal-title":"Dermatology"},{"key":"10.1111\/bjd.13932-BIB0003|bjd13932-cit-0003","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jaad.2004.10.862","article-title":"Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey","volume":"52","author":"Nijsten","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.13932-BIB0004|bjd13932-cit-0004","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1087-0024.2003.09102.x","article-title":"Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction","volume":"9","author":"Stern","year":"2004","journal-title":"J Investig Dermatol Symp Proc"},{"key":"10.1111\/bjd.13932-BIB0005|bjd13932-cit-0005","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/bjd.13932-BIB0006|bjd13932-cit-0006","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"10.1111\/bjd.13932-BIB0007|bjd13932-cit-0007","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/jdv.12177","article-title":"Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study","volume":"28","author":"Papp","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.13932-BIB0008|bjd13932-cit-0008","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/jid.2011.304","article-title":"A phase III, randomized, controlled trial of the fully human IL-12\/23 mAb briakinumab in moderate-to-severe psoriasis","volume":"132","author":"Gordon","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.13932-BIB0009|bjd13932-cit-0009","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1084\/jem.20060244","article-title":"IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis","volume":"203","author":"Chan","year":"2006","journal-title":"J Exp Med"},{"key":"10.1111\/bjd.13932-BIB0010|bjd13932-cit-0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"10.1111\/bjd.13932-BIB0011|bjd13932-cit-0011","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin (IL)-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"key":"10.1111\/bjd.13932-BIB0012|bjd13932-cit-0012","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2014.01.025","article-title":"Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis","volume":"133","author":"Sofen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.13932-BIB0013|bjd13932-cit-0013","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"10.1111\/bjd.13932-BIB0014|bjd13932-cit-0014","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1111\/bjd.13932-BIB0015|bjd13932-cit-0015","doi-asserted-by":"crossref","first-page":"52ra72","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1111\/bjd.13932-BIB0016|bjd13932-cit-0016","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jaci.2012.04.024","article-title":"IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis","volume":"130","author":"Krueger","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1111\/bjd.13932-BIB0017|bjd13932-cit-0017","doi-asserted-by":"crossref","first-page":"5688","DOI":"10.4049\/jimmunol.1001538","article-title":"Cutting edge: a critical functional role for IL-23 in psoriasis","volume":"185","author":"Tonel","year":"2010","journal-title":"J Immunol"},{"key":"10.1111\/bjd.13932-BIB0018|bjd13932-cit-0018","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1128\/IAI.00621-06","article-title":"Neutralization or absence of the interleukin-23 pathway does not compromise immunity to mycobacterial infection","volume":"74","author":"Chackerian","year":"2006","journal-title":"Infect Immun"},{"key":"10.1111\/bjd.13932-BIB0019|bjd13932-cit-0019","doi-asserted-by":"crossref","first-page":"5453","DOI":"10.4049\/jimmunol.1001153","article-title":"IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans","volume":"185","author":"Kagami","year":"2010","journal-title":"J Immunol"},{"key":"10.1111\/bjd.13932-BIB0020|bjd13932-cit-0020","doi-asserted-by":"crossref","first-page":"7891","DOI":"10.4049\/jimmunol.181.11.7891","article-title":"Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17","volume":"181","author":"Schulz","year":"2008","journal-title":"J Immunol"},{"key":"10.1111\/bjd.13932-BIB0021|bjd13932-cit-0021","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/0008-5472.CAN-12-1337","article-title":"Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state","volume":"72","author":"Teng","year":"2012","journal-title":"Cancer Res"},{"key":"10.1111\/bjd.13932-BIB0022|bjd13932-cit-0022","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature11465","article-title":"Adenoma-linked barrier defects and microbial products drive IL-23\/IL-17-mediated tumour growth","volume":"491","author":"Grivennikov","year":"2012","journal-title":"Nature"},{"key":"10.1111\/bjd.13932-BIB0023|bjd13932-cit-0023","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1038\/jid.2011.469","article-title":"IL-12 and IL-23 affect photocarcinogenesis differently","volume":"132","author":"Jantschitsch","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.13932-BIB0024|bjd13932-cit-0024","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature04808","article-title":"IL-23 promotes tumour incidence and growth","volume":"442","author":"Langowski","year":"2006","journal-title":"Nature"},{"key":"10.1111\/bjd.13932-BIB0025|bjd13932-cit-0025","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1158\/0008-5472.CAN-05-3614","article-title":"Enhanced photocarcinogenesis in interleukin-12-deficient mice","volume":"66","author":"Maeda","year":"2006","journal-title":"Cancer Res"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.13932","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.13932","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.13932\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:16:02Z","timestamp":1676366162000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/173\/4\/930\/6616059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.13932","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}